Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 10, 2012, Pages 1676-1685

  Vacas, Eva ^a   Fernández Martínez, Ana B ^a   Bajo, Ana M ^a   Sánchez Chapado, Manuel ^a,b   Schally, Andrew V ^c,d   Prieto, Juan C ^a   Carmena, María J ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

CAMP; FPRL 1; PI3 K; Proliferation; RCC; VIP

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ADENYLATE CYCLASE; CYCLIC AMP; FORMYLPEPTIDE RECEPTOR LIKE 1; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; MESSENGER RNA; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; STAT3 PROTEIN; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; EPITHELIUM CELL; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; KIDNEY TUBULE CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIC AMP; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SPACE; KIDNEY NEOPLASMS; MICE; MICE, NUDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; VASOACTIVE INTESTINAL PEPTIDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864744509     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.06.018     Document Type: Article

References (41)

1. Cohen H.T., Mc Goven F.J. Renal-cell carcinoma. N. Engl. J. Med. 2005, 353:2477-2490.
2. Ljungberg B., Campbell S.C., Cho H.Y., Jackmin D., Lee J.E., Weikert S., Kiemeney L.A. The epidemiology of renal cell carcinoma. Eur. Urol. 2011, 60:615-621.
3. Algaba F., Akaza H., López-Beltrán A., Martignoni G., Moch H., Montironi R., Reuter V. Current pathology keys of renal cell carcinoma. Eur. Urol. 2011, 60:634-643.
4. Kirkali Z., Lekili M. Renal cell carcinoma: new prognostic factors?. Curr. Opin. Urol. 2003, 13:433-438.
5. Motzer R.J., Bukowski R.M. Targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 2006, 24:5601-5608.
6. Eichelberg C., Junker K., Ljungberg B., Moch H. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur. Urol. 2009, 55:851-863.
7. Yu H., Jove R. The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 2004, 4:97-105.
8. Yu H., Pardoll D., Jove R. STATs in cancer, inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
9. Yang J., Stark G.R. Roles of unphosphorylated STATs in signaling. Cell Res. 2008, 18:443-451.
10. Hodge D.R., Hurt E.M., Farrar W.L. The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer 2005, 41:2502-2512.
11. Wang J., Ouyang C., Chen X., Fu B., Lu Y., Hong Q. STAT3 inhibits apoptosis of human renal tubular epithelial cells induced by ATP depletion/recovery. Nephron Exp. Nephrol. 2008, 108:e11-e18.
12. Agarwal B.B., Kunnumakkara A.B., Harikumar K.B., Gupta S.R., Tharakan S.T., Koka C., Dey S., Sung B. Signal transducer and activator of transcription-3, inflammation and cancer. Ann. N. Y. Acad. Sci. 2009, 1171:59-76.
13. Horiguchi A., Oya M., Shimada T., Uchida A., Marumo K., Murai M. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J. Urol. 2002, 168:762-765.
14. Masuda A., Kamai T., Abe H., Arai K., Yoshida K. Is STAT3 and/or p53 mRNA expression a prognostic marker for renal cell carcinoma?. Biomed. Res. 2009, 30:171-176.
15. Laburthe M., Couvineau A., Marie J.C. VPAC receptors for VIP and PACAP. Recept. Channels 2002, 8:131-153.
16. Laburthe M., Couvineau A., Tan V. Class II G-protein coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 2007, 28:1631-1639.
17. El Zein N., Badran B., Sariban E. VIP differentially activates beta2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type I and FPRL1. J. Leukoc. Biol. 2008, 72:972-981.
18. Borland G., Smith B.O., Yarwood S.J. EPAC proteins transduce diverse cellular actions of cAMP. Br. J. Pharmacol. 2009, 158:70-86.
19. Horvath G., Brubel R., Kovacs K., Reglodi D., Opper B., Ferencz A., Szakaly P., Laszlo E., Hau L., Kiss P., Tamas A., Racz B. Effects of PACAP on oxidative stress-induced cell death in rat kidney and human hepatocyte cells. J. Mol. Neurosci. 2010, 484:148-152.
20. Li, Maderdrut J.L., Lertora J.J.L., Arimura A., Batuman V. Renoprotection by pituitary adenylate cyclase-activating polypeptide in multiple myeloma and other kidney diseases. Regul. Pept. 2008, 145:24-32.
21. Muller J.M., Philipe M., Chevrier L., Heraud C., Alleaume C., Chadeneau C. The VIP-receptor system in neuroblastoma cells. Regul. Pept. 2006, 137:34-41.
22. Absood A., Hu B., Bassily N., Colletti L. VIP inhibits human HepG2 cell proliferation in vitro. Regul. Pept. 2008, 146:285-292.
23. Gilman A.G. A protein binding assay for adenosine 3'-5'-cyclic monophosphate. Proc. Natl. Acad. Sci. U.S.A. 1970, 67:305-312.
24. Varga J.L., Schally A.V., Csernus V.J., Zarandi M., Halmos G., Groot K., Rekasi Z. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:692-697.
25. Rekasi Z., Varga J.L., Schally A.V., Halmos G., Groot K., Czompoly T. Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:1218-1223.
26. Juarranz M.G., Bolaños O., Gutiérrez-Cañas I., Lerner E.A., Robberecht P., Carmena M.J., Prieto J.C., Rodríguez-Henche N. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors. Cell. Signal. 2001, 13:887-894.
27. Fernández-Martínez A.B., Collado B., Bajo A.M., Sánchez-Chapado M., Prieto J.C., Carmena M.J. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-κB in human prostate cell lines. Differential time-dependent responses in cancer progression. Mol. Cell. Endocrinol. 2007, 270:8-16.
28. Fernández-Martinez A.B., Bajo A.M., Sánchez-Chapado M., Prieto J.C., Carmena M.J. Vasoactive intestinal peptide behaves as a prometastatic factor in human prostate cancer cells. Prostate 2009, 63:774-786.
29. Fernández-Martínez A.B., Bajo A.M., Arenas M.I., Sánchez-Chapado M., Prieto J.C., Carmena M.J. Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1. Cancer Lett. 2010, 299:11-21.
30. Valdehita A., Carmena M.J., Collado B., Prieto J.C., Bajo A. Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells. Regul. Pept. 2007, 144:101-108.
31. Valdehita A., Bajo A.M., Schally A.V., Varga J.L., Carmena M.J., Prieto J.C. Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells. Mol. Cell. Endocrinol. 2009, 302:341-348.
32. Valdehita A., Bajo A.M., Fernández-Martínez A.B., Arenas M.I., Vacas E., Valenzuela P., Ruíz-Villaespesa A., Prieto J.C., Carmena M.J. Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer. Peptides 2010, 31:2035-2045.
33. Gutiérrez-Cañas I., Juarranz M.G., Collado B., Rodríguez-Henche N., Chiloeches A., Prieto J.C., Carmena M.J. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K. Prostate 2005, 63:44-55.
34. Jungwirth A., Schally A.V., Pinski J., Groot K., Armatis P., Halmos G. Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:5810-5813.
35. Halmos G., Schally A.V., Varga J.L., Plonowski A., Rekasi Z., Czompoly T. Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:10555-10560.
36. 2+ signalling. Implications in angiogenesis and neuroendocrine differentiation. Biochim. Biophys. Acta 2005, 1744:224-233.
37. 1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells. Mol. Cell. Endocrinol. 2012, 348:241-246.
38. Casanueva F.F., Camiña J.P., Carreira M.C., Pazos Y., Varga J.L., Schally A.V. Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:20452-20457.
39. Maruno K., Said S.I. VIP inhibits the proliferation of small-cell and nonsmall-cell lung carcinoma. Ann. N. Y. Acad. Sci. 1996, 805:389-392.
40. Maruno K., Absood A., Said S. Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:14373-14378.
41. Sokolowska P., Nowak J.Z. Effects of PACAP and VIP on cAMP-generating system and proliferation of C6 glioma cells. J. Mol. Neurosci. 2008, 36:286-291.